Trial Outcomes & Findings for Factors Affecting Mortality in Critical Patients Admitted to Intensive Care Unit Due to Coronavirus Disease 2019 (NCT NCT04659876)
NCT ID: NCT04659876
Last Updated: 2026-01-12
Results Overview
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Recruitment status
COMPLETED
Target enrollment
445 participants
Primary outcome timeframe
At ICU admission (first laboratory measurement after ICU admission)
Results posted on
2026-01-12
Participant Flow
Participant milestones
| Measure |
Grup S (Survivors)
Survivors in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
Grup NS (Nonsurvivors)
Patients who died in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
|---|---|---|
|
Overall Study
STARTED
|
149
|
296
|
|
Overall Study
COMPLETED
|
149
|
296
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Race and Ethnicity were not collected from any participant.
Baseline characteristics by cohort
| Measure |
Grup S (Survivors)
n=149 Participants
Survivors in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
Grup NS (Nonsurvivors)
n=296 Participants
Patients who died in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
Total
n=445 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
62.7 years
n=149 Participants
|
71.4 years
n=296 Participants
|
68.5 years
n=445 Participants
|
|
Sex: Female, Male
Female
|
83 Participants
n=149 Participants
|
130 Participants
n=296 Participants
|
213 Participants
n=445 Participants
|
|
Sex: Female, Male
Male
|
66 Participants
n=149 Participants
|
166 Participants
n=296 Participants
|
232 Participants
n=445 Participants
|
|
Race and Ethnicity Not Collected
|
—
|
—
|
0 Participants
Race and Ethnicity were not collected from any participant.
|
|
Comorbidity
No
|
42 Participants
n=149 Participants
|
65 Participants
n=296 Participants
|
107 Participants
n=445 Participants
|
|
Comorbidity
Yes
|
107 Participants
n=149 Participants
|
231 Participants
n=296 Participants
|
338 Participants
n=445 Participants
|
PRIMARY outcome
Timeframe: APACHE II score on the first admission of ICUPopulation: APACHE II score
The score can help in the assessment of patients to determine the level \& degree of diagnostic \& therapeutic intervention. Interpretation of APACHE II: minimum 0 and maximum 71; increasing score is associated with an increasing risk of hospital death.
Outcome measures
| Measure |
SOFA Score Grup S (Survivors)
n=149 Participants
Survivors in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
SOFA Score Grup NS (Nonsurvivors)
n=296 Participants
Patients who died in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
|---|---|---|
|
Acute Physiology and Chronic Health Evaluation II Score
|
13.1 score on a scale
Interval 2.0 to 33.0
|
18.3 score on a scale
Interval 2.0 to 49.0
|
PRIMARY outcome
Timeframe: SOFA score on the first admission of ICUThe Sequential Organ Failure Assessment (SOFA) score is a scoring system that assesses the performance of several organ systems in the body (neurologic, blood, liver, kidney, and blood pressure/hemodynamics) and assigns a score based on the data obtained in each category. The SOFA score is made of 6 variables, each representing an organ system. Each organ system is assigned a point value from 0 (normal) to 4 (high degree of dysfunction/failure). Score ranges from 0 (best) to 24 (worst) points.
Outcome measures
| Measure |
SOFA Score Grup S (Survivors)
n=149 Participants
Survivors in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
SOFA Score Grup NS (Nonsurvivors)
n=296 Participants
Patients who died in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
|---|---|---|
|
Sequential Organ Failure Assessment Score
|
3.3 units on a scale
Interval 1.0 to 12.0
|
4.8 units on a scale
Interval 1.0 to 17.0
|
PRIMARY outcome
Timeframe: When the patients were admitted to ICU for the first time.It is a system used to determine the severity of kidney failure. It is a classification consisting of four stages: 0-1-2-3. It indicates that the level of failure worsens as the stage increases.
Outcome measures
| Measure |
SOFA Score Grup S (Survivors)
n=149 Participants
Survivors in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
SOFA Score Grup NS (Nonsurvivors)
n=296 Participants
Patients who died in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
|---|---|---|
|
Kidney Disease: Improving Global Outcomes Scores
KDIGO 0
|
113 Participants
|
76 Participants
|
|
Kidney Disease: Improving Global Outcomes Scores
KDIGO 1
|
17 Participants
|
66 Participants
|
|
Kidney Disease: Improving Global Outcomes Scores
KDIGO 2
|
12 Participants
|
67 Participants
|
|
Kidney Disease: Improving Global Outcomes Scores
KDIGO 3
|
7 Participants
|
87 Participants
|
PRIMARY outcome
Timeframe: At ICU admissionPopulation: All participants included in the study were analyzed for this outcome. The numbers analyzed are identical to those reported in the participant flow.
White blood cell count was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Outcome measures
| Measure |
SOFA Score Grup S (Survivors)
n=149 Participants
Survivors in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
SOFA Score Grup NS (Nonsurvivors)
n=296 Participants
Patients who died in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
|---|---|---|
|
White Blood Cell
|
10.6 cells × 10³/µL
Interval 2.95 to 42.7
|
11.6 cells × 10³/µL
Interval 1.13 to 57.4
|
PRIMARY outcome
Timeframe: When the patients were admitted to ICU for the first timePopulation: All participants included in the study were analyzed for this outcome. The numbers analyzed are identical to those reported in the participant flow.
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Outcome measures
| Measure |
SOFA Score Grup S (Survivors)
n=149 Participants
Survivors in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
SOFA Score Grup NS (Nonsurvivors)
n=296 Participants
Patients who died in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
|---|---|---|
|
Neutrophil
|
8.75 cells × 10³/µL
Interval 1.3 to 37.5
|
9.9 cells × 10³/µL
Interval 0.66 to 34.4
|
PRIMARY outcome
Timeframe: When the patients were admitted to ICU for the first timePopulation: All participants included in the study were analyzed for this outcome. The numbers analyzed are identical to those reported in the participant flow.
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Outcome measures
| Measure |
SOFA Score Grup S (Survivors)
n=149 Participants
Survivors in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
SOFA Score Grup NS (Nonsurvivors)
n=296 Participants
Patients who died in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
|---|---|---|
|
Lymphocyte
|
1.1 cells × 10³/µL
Interval 0.19 to 3.59
|
0.93 cells × 10³/µL
Interval 0.14 to 3.5
|
PRIMARY outcome
Timeframe: the first admission to ICUPopulation: All participants included in the study were analyzed for this outcome. The numbers analyzed are identical to those reported in the participant flow.
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Outcome measures
| Measure |
SOFA Score Grup S (Survivors)
n=149 Participants
Survivors in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
SOFA Score Grup NS (Nonsurvivors)
n=296 Participants
Patients who died in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
|---|---|---|
|
Neutrophil Lymphocyte Ratio
|
9.4 Ratio
Interval 0.33 to 60.04
|
14.5 Ratio
Interval 0.12 to 87.1
|
PRIMARY outcome
Timeframe: When the patients were admitted to ICU for the first timePopulation: All participants included in the study were analyzed for this outcome. The numbers analyzed are identical to those reported in the participant flow.
The presence of this comorbidity was determined based on medical history documented in medical records at ICU admission.
Outcome measures
| Measure |
SOFA Score Grup S (Survivors)
n=149 Participants
Survivors in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
SOFA Score Grup NS (Nonsurvivors)
n=296 Participants
Patients who died in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
|---|---|---|
|
Comorbidities
No
|
42 Participants
|
65 Participants
|
|
Comorbidities
Yes
|
107 Participants
|
231 Participants
|
PRIMARY outcome
Timeframe: When the patients were admitted to ICU for the first timePopulation: All participants included in the study were analyzed for this outcome. The numbers analyzed are identical to those reported in the participant flow.
The presence of this comorbidity was determined based on medical history documented in medical records at ICU admission.
Outcome measures
| Measure |
SOFA Score Grup S (Survivors)
n=149 Participants
Survivors in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
SOFA Score Grup NS (Nonsurvivors)
n=296 Participants
Patients who died in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
|---|---|---|
|
Diabetes
|
38 Participants
|
89 Participants
|
PRIMARY outcome
Timeframe: When the patients were admitted to ICU for the first timePopulation: All participants included in the study were analyzed for this outcome. The numbers analyzed are identical to those reported in the participant flow.
The presence of this comorbidity was determined based on medical history documented in medical records at ICU admission.
Outcome measures
| Measure |
SOFA Score Grup S (Survivors)
n=149 Participants
Survivors in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
SOFA Score Grup NS (Nonsurvivors)
n=296 Participants
Patients who died in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
|---|---|---|
|
Hypertension
|
64 Participants
|
114 Participants
|
PRIMARY outcome
Timeframe: When the patients were admitted to ICU for the first timePopulation: All participants included in the study were analyzed for this outcome. The numbers analyzed are identical to those reported in the participant flow.
The presence of this comorbidity was determined based on medical history documented in medical records at ICU admission.
Outcome measures
| Measure |
SOFA Score Grup S (Survivors)
n=149 Participants
Survivors in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
SOFA Score Grup NS (Nonsurvivors)
n=296 Participants
Patients who died in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
|---|---|---|
|
Chronic Obstructive Pulmonary Disease
|
19 Participants
|
26 Participants
|
PRIMARY outcome
Timeframe: When the patients were admitted to ICU for the first timePopulation: All participants included in the study were analyzed for this outcome. The numbers analyzed are identical to those reported in the participant flow.
The presence of this comorbidity was determined based on medical history documented in medical records at ICU admission.
Outcome measures
| Measure |
SOFA Score Grup S (Survivors)
n=149 Participants
Survivors in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
SOFA Score Grup NS (Nonsurvivors)
n=296 Participants
Patients who died in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
|---|---|---|
|
Chronic Kidney Disease
|
12 Participants
|
22 Participants
|
PRIMARY outcome
Timeframe: When the patients were admitted to ICU for the first timePopulation: All participants included in the study were analyzed for this outcome. The numbers analyzed are identical to those reported in the participant flow.
The presence of this comorbidity was determined based on medical history documented in medical records at ICU admission.
Outcome measures
| Measure |
SOFA Score Grup S (Survivors)
n=149 Participants
Survivors in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
SOFA Score Grup NS (Nonsurvivors)
n=296 Participants
Patients who died in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
|---|---|---|
|
Cardiovascular Disease
|
19 Participants
|
47 Participants
|
PRIMARY outcome
Timeframe: At ICU admission (first laboratory measurement after ICU admission)Population: All participants included in the study were analyzed for this outcome. The numbers analyzed are identical to those reported in the participant flow.
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Outcome measures
| Measure |
SOFA Score Grup S (Survivors)
n=149 Participants
Survivors in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
SOFA Score Grup NS (Nonsurvivors)
n=296 Participants
Patients who died in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
|---|---|---|
|
Hemoglobin
|
13.06 g/dl
Interval 5.9 to 17.0
|
12.6 g/dl
Interval 5.6 to 19.2
|
PRIMARY outcome
Timeframe: At ICU admission (first laboratory measurement after ICU admission)Population: All participants included in the study were analyzed for this outcome. The numbers analyzed are identical to those reported in the participant flow.
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Outcome measures
| Measure |
SOFA Score Grup S (Survivors)
n=149 Participants
Survivors in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
SOFA Score Grup NS (Nonsurvivors)
n=296 Participants
Patients who died in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
|---|---|---|
|
Hematocrit
|
40.61 percentage of red blood cell
Interval 17.8 to 61.6
|
41.2 percentage of red blood cell
Interval 20.2 to 55.9
|
PRIMARY outcome
Timeframe: At ICU admission (first laboratory measurement after ICU admission)Population: All participants included in the study were analyzed for this outcome. The numbers analyzed are identical to those reported in the participant flow.
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Outcome measures
| Measure |
SOFA Score Grup S (Survivors)
n=149 Participants
Survivors in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
SOFA Score Grup NS (Nonsurvivors)
n=296 Participants
Patients who died in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
|---|---|---|
|
Platelet
|
253.4 ×1000/uL
Interval 84.0 to 671.0
|
237.3 ×1000/uL
Interval 30.0 to 628.0
|
PRIMARY outcome
Timeframe: At ICU admission (first laboratory measurement after ICU admission)Population: All participants included in the study were analyzed for this outcome. The numbers analyzed are identical to those reported in the participant flow.
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Outcome measures
| Measure |
SOFA Score Grup S (Survivors)
n=149 Participants
Survivors in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
SOFA Score Grup NS (Nonsurvivors)
n=296 Participants
Patients who died in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
|---|---|---|
|
Prothrombin Time
|
13.3 second
Interval 9.9 to 22.5
|
14.1 second
Interval 9.7 to 54.9
|
PRIMARY outcome
Timeframe: At ICU admission (first laboratory measurement after ICU admission)Population: All participants included in the study were analyzed for this outcome. The numbers analyzed are identical to those reported in the participant flow.
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Outcome measures
| Measure |
SOFA Score Grup S (Survivors)
n=149 Participants
Survivors in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
SOFA Score Grup NS (Nonsurvivors)
n=296 Participants
Patients who died in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
|---|---|---|
|
D-dimer
|
954.5 ng/ml
Interval 75.0 to 16948.0
|
2564.4 ng/ml
Interval 8.4 to 44498.0
|
PRIMARY outcome
Timeframe: At ICU admission (first laboratory measurement after ICU admission)Population: All participants included in the study were analyzed for this outcome. The numbers analyzed are identical to those reported in the participant flow.
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Outcome measures
| Measure |
SOFA Score Grup S (Survivors)
n=149 Participants
Survivors in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
SOFA Score Grup NS (Nonsurvivors)
n=296 Participants
Patients who died in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
|---|---|---|
|
Blood Gas Analysis-pH
|
7.38 Quantitative measure of the acidity
Interval 6.91 to 7.54
|
7.36 Quantitative measure of the acidity
Interval 6.82 to 7.55
|
PRIMARY outcome
Timeframe: At ICU admission (first laboratory measurement after ICU admission)Population: All participants included in the study were analyzed for this outcome. The numbers analyzed are identical to those reported in the participant flow.
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Outcome measures
| Measure |
SOFA Score Grup S (Survivors)
n=149 Participants
Survivors in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
SOFA Score Grup NS (Nonsurvivors)
n=296 Participants
Patients who died in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
|---|---|---|
|
Partial Oxygen Pressure
|
42.14 mmHg
Interval 17.9 to 162.0
|
40.3 mmHg
Interval 13.5 to 198.0
|
PRIMARY outcome
Timeframe: At ICU admission (first laboratory measurement after ICU admission)Population: All participants included in the study were analyzed for this outcome. The numbers analyzed are identical to those reported in the participant flow.
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Outcome measures
| Measure |
SOFA Score Grup S (Survivors)
n=149 Participants
Survivors in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
SOFA Score Grup NS (Nonsurvivors)
n=296 Participants
Patients who died in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
|---|---|---|
|
Partial Pressure of Carbon Dioxide
|
39.1 mmHg
Interval 16.9 to 108.0
|
38.61 mmHg
Interval 20.0 to 115.0
|
PRIMARY outcome
Timeframe: At ICU admission (first laboratory measurement after ICU admission)Population: All participants included in the study were analyzed for this outcome. The numbers analyzed are identical to those reported in the participant flow.
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Outcome measures
| Measure |
SOFA Score Grup S (Survivors)
n=149 Participants
Survivors in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
SOFA Score Grup NS (Nonsurvivors)
n=296 Participants
Patients who died in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
|---|---|---|
|
Bicarbonate
|
23.02 mmol/L
Interval 5.9 to 31.5
|
21.16 mmol/L
Interval 5.3 to 32.1
|
PRIMARY outcome
Timeframe: At ICU admission (first laboratory measurement after ICU admission)Population: All participants included in the study were analyzed for this outcome. The numbers analyzed are identical to those reported in the participant flow.
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Outcome measures
| Measure |
SOFA Score Grup S (Survivors)
n=149 Participants
Survivors in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
SOFA Score Grup NS (Nonsurvivors)
n=296 Participants
Patients who died in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
|---|---|---|
|
Lactate
|
2.2 mmol/L
Interval 0.6 to 8.2
|
3.04 mmol/L
Interval 0.7 to 26.0
|
PRIMARY outcome
Timeframe: At ICU admission (first laboratory measurement after ICU admission)Population: All participants included in the study were analyzed for this outcome. The numbers analyzed are identical to those reported in the participant flow.
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Outcome measures
| Measure |
SOFA Score Grup S (Survivors)
n=149 Participants
Survivors in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
SOFA Score Grup NS (Nonsurvivors)
n=296 Participants
Patients who died in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
|---|---|---|
|
Lactate Dehydrogenase
|
406.7 U/L
Interval 139.0 to 1079.0
|
569.4 U/L
Interval 99.0 to 4500.0
|
PRIMARY outcome
Timeframe: At ICU admission (first laboratory measurement after ICU admission)Population: All participants included in the study were analyzed for this outcome. The numbers analyzed are identical to those reported in the participant flow.
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Outcome measures
| Measure |
SOFA Score Grup S (Survivors)
n=149 Participants
Survivors in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
SOFA Score Grup NS (Nonsurvivors)
n=296 Participants
Patients who died in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
|---|---|---|
|
Creatine Kinase
|
204.4 IU/L
Interval 11.0 to 2949.0
|
369.4 IU/L
Interval 0.32 to 14952.0
|
PRIMARY outcome
Timeframe: At ICU admission (first laboratory measurement after ICU admission)Population: All participants included in the study were analyzed for this outcome. The numbers analyzed are identical to those reported in the participant flow.
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Outcome measures
| Measure |
SOFA Score Grup S (Survivors)
n=149 Participants
Survivors in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
SOFA Score Grup NS (Nonsurvivors)
n=296 Participants
Patients who died in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
|---|---|---|
|
C-reactive Protein
|
120.4 mg/L
Interval 2.0 to 350.0
|
151.7 mg/L
Interval 2.0 to 350.0
|
PRIMARY outcome
Timeframe: At ICU admission (first laboratory measurement after ICU admission)Population: All participants included in the study were analyzed for this outcome. The numbers analyzed are identical to those reported in the participant flow.
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Outcome measures
| Measure |
SOFA Score Grup S (Survivors)
n=149 Participants
Survivors in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
SOFA Score Grup NS (Nonsurvivors)
n=296 Participants
Patients who died in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
|---|---|---|
|
Blood Urea Nitrogen
|
47.6 mg/dl
Interval 8.0 to 267.0
|
72.5 mg/dl
Interval 13.0 to 280.0
|
PRIMARY outcome
Timeframe: At ICU admission (first laboratory measurement after ICU admission)Population: All participants included in the study were analyzed for this outcome. The numbers analyzed are identical to those reported in the participant flow.
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Outcome measures
| Measure |
SOFA Score Grup S (Survivors)
n=149 Participants
Survivors in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
SOFA Score Grup NS (Nonsurvivors)
n=296 Participants
Patients who died in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
|---|---|---|
|
Creatinine
|
1.28 mg/dl
Interval 0.44 to 10.4
|
1.68 mg/dl
Interval 0.36 to 21.8
|
PRIMARY outcome
Timeframe: At ICU admission (first laboratory measurement after ICU admission)Population: All participants included in the study were analyzed for this outcome. The numbers analyzed are identical to those reported in the participant flow.
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Outcome measures
| Measure |
SOFA Score Grup S (Survivors)
n=149 Participants
Survivors in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
SOFA Score Grup NS (Nonsurvivors)
n=296 Participants
Patients who died in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
|---|---|---|
|
Alanine Aminotransferase
|
32.2 U/L
Interval 6.0 to 442.0
|
47.9 U/L
Interval 6.0 to 1254.0
|
PRIMARY outcome
Timeframe: At ICU admission (first laboratory measurement after ICU admission)Population: All participants included in the study were analyzed for this outcome. The numbers analyzed are identical to those reported in the participant flow.
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Outcome measures
| Measure |
SOFA Score Grup S (Survivors)
n=149 Participants
Survivors in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
SOFA Score Grup NS (Nonsurvivors)
n=296 Participants
Patients who died in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
|---|---|---|
|
Aspartate Aminotransferase
|
40.8 U/L
Interval 9.0 to 518.0
|
81.5 U/L
Interval 7.0 to 3444.0
|
PRIMARY outcome
Timeframe: At ICU admission (first laboratory measurement after ICU admission)Population: All participants included in the study were analyzed for this outcome. The numbers analyzed are identical to those reported in the participant flow.
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Outcome measures
| Measure |
SOFA Score Grup S (Survivors)
n=149 Participants
Survivors in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
SOFA Score Grup NS (Nonsurvivors)
n=296 Participants
Patients who died in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
|---|---|---|
|
Total Bilirubin
|
0.68 mg/dl
Interval 0.14 to 3.69
|
0.75 mg/dl
Interval 0.12 to 6.8
|
PRIMARY outcome
Timeframe: At ICU admission (first laboratory measurement after ICU admission)Population: All participants included in the study were analyzed for this outcome. The numbers analyzed are identical to those reported in the participant flow.
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Outcome measures
| Measure |
SOFA Score Grup S (Survivors)
n=149 Participants
Survivors in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
SOFA Score Grup NS (Nonsurvivors)
n=296 Participants
Patients who died in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
|---|---|---|
|
Direct Bilirubin
|
0.34 mg/dl
Interval 0.1 to 2.31
|
0.4 mg/dl
Interval 0.1 to 4.7
|
PRIMARY outcome
Timeframe: At ICU admission (first laboratory measurement after ICU admission)Population: All participants included in the study were analyzed for this outcome. The numbers analyzed are identical to those reported in the participant flow.
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Outcome measures
| Measure |
SOFA Score Grup S (Survivors)
n=149 Participants
Survivors in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
SOFA Score Grup NS (Nonsurvivors)
n=296 Participants
Patients who died in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
|---|---|---|
|
Indirect Bilirubin
|
0.33 mg/dl
Interval 0.03 to 1.86
|
0.33 mg/dl
Interval 0.01 to 2.0
|
PRIMARY outcome
Timeframe: At ICU admission (first laboratory measurement after ICU admission)Population: All participants included in the study were analyzed for this outcome. The numbers analyzed are identical to those reported in the participant flow.
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Outcome measures
| Measure |
SOFA Score Grup S (Survivors)
n=149 Participants
Survivors in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
SOFA Score Grup NS (Nonsurvivors)
n=296 Participants
Patients who died in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
|---|---|---|
|
Procalcitonin
|
1.39 ng/ml
Interval 0.02 to 62.8
|
4.13 ng/ml
Interval 0.03 to 100.0
|
PRIMARY outcome
Timeframe: At ICU admission (first laboratory measurement after ICU admission)Population: All participants included in the study were analyzed for this outcome. The numbers analyzed are identical to those reported in the participant flow.
This parameter was measured using routinely collected laboratory data obtained from medical records at ICU admission.
Outcome measures
| Measure |
SOFA Score Grup S (Survivors)
n=149 Participants
Survivors in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
SOFA Score Grup NS (Nonsurvivors)
n=296 Participants
Patients who died in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
|---|---|---|
|
Ferritin
|
673.8 μg/L
Interval 5.86 to 2000.0
|
951.5 μg/L
Interval 16.6 to 2000.0
|
SECONDARY outcome
Timeframe: Three monthsPopulation: All participants included in the study were analyzed for this outcome. The numbers analyzed are identical to those reported in the participant flow.
ICU length of stay was measured as the total number of days from ICU admission to ICU discharge or death, based on information recorded in medical records.
Outcome measures
| Measure |
SOFA Score Grup S (Survivors)
n=149 Participants
Survivors in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
SOFA Score Grup NS (Nonsurvivors)
n=296 Participants
Patients who died in ICU follow-up
clinical features and laboratory values: Patients' age, gender, comorbidity, ABO and Rh blood groups, APACHE II, SOFA and KDIGO scores when first admitted to the ICU, performing hemogram (WBC, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, PO2, PCO2, HCO3, lactate), coagulation parameters PTZ and D-dimer, blood biochemistry results (CRP, LDH, CK, urea, creatinine, ALT, AST, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded.
|
|---|---|---|
|
Length of Stay in the Intensive Care Unit
|
13.02 Day
Interval 1.0 to 91.0
|
10.3 Day
Interval 1.0 to 79.0
|
Adverse Events
Grup S (Survivors)
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Grup NS (Nonsurvivors)
Serious events: 0 serious events
Other events: 0 other events
Deaths: 296 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Osman Uzundere
SBU Gazi Yaşargil Training and Research Hospital
Phone: +905330206362
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place